Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma

Nuvation Bio Inc. (NYSE:NUVB) is one of the best cancer stocks to invest in now. On February 9, Nuvation Bio Inc. (NYSE:NUVB) finalized a protocol amendment to an ongoing global SIGMA study of safusidenib. The company is evaluating the efficacy and safety of safusidenib in patients with high-risk or high-grade IDH1-mutant astrocytoma.

The amended protocol expands patient eligibility in the registration portion of the trial. It will also enroll a non-pivotal single-arm cohort to examine the efficacy and safety of safusidenib in chemotherapy- and radiotherapy-naïve patients. The company has already delivered positive Phase 2 trial results, including both astrocytoma and oligodendroglioma.

“These SIGMA protocol updates reflect alignment with U.S. regulators to support the potential approval of safusidenib as swiftly as possible for a patient population that is in dire need of options,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Nuvation Bio Inc. (NYSE:NUVB) has already reiterated its commitment to identifying biomarkers and targeting specific mutations to develop precise therapies. It is part of a broader plan to address critical needs in oncology.

While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.